AR052479A1 - Polimorfo del 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) y su uso - Google Patents

Polimorfo del 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) y su uso

Info

Publication number
AR052479A1
AR052479A1 ARP060100451A ARP060100451A AR052479A1 AR 052479 A1 AR052479 A1 AR 052479A1 AR P060100451 A ARP060100451 A AR P060100451A AR P060100451 A ARP060100451 A AR P060100451A AR 052479 A1 AR052479 A1 AR 052479A1
Authority
AR
Argentina
Prior art keywords
cci
polymorph
degree
hydroximethyl
rapamycin
Prior art date
Application number
ARP060100451A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR052479A1 publication Critical patent/AR052479A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP060100451A 2005-02-09 2006-02-08 Polimorfo del 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) y su uso AR052479A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65137405P 2005-02-09 2005-02-09

Publications (1)

Publication Number Publication Date
AR052479A1 true AR052479A1 (es) 2007-03-21

Family

ID=36570939

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100451A AR052479A1 (es) 2005-02-09 2006-02-08 Polimorfo del 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) y su uso

Country Status (19)

Country Link
US (1) US7442707B2 (enExample)
EP (1) EP1856130A1 (enExample)
JP (1) JP2008530090A (enExample)
KR (1) KR20070107030A (enExample)
CN (1) CN101115759A (enExample)
AR (1) AR052479A1 (enExample)
AU (1) AU2006213061A1 (enExample)
BR (1) BRPI0607932A2 (enExample)
CA (1) CA2595766A1 (enExample)
CR (1) CR9257A (enExample)
GT (1) GT200600044A (enExample)
IL (1) IL184560A0 (enExample)
MX (1) MX2007009590A (enExample)
NO (1) NO20073725L (enExample)
PE (1) PE20060996A1 (enExample)
RU (1) RU2007129264A (enExample)
TW (1) TW200638932A (enExample)
WO (1) WO2006086172A1 (enExample)
ZA (1) ZA200706628B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
PE20070748A1 (es) * 2005-12-07 2007-08-08 Wyeth Corp Proceso ajustable a escala para la preparacion de un 42-ester de rapamicina a partir de un boronato de 42-ester de rapamicina
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
CA2749807C (en) * 2009-01-21 2015-09-29 Biocon Limited A method for determination of sirolimus stability and process for preparing its stable form
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US6680330B2 (en) * 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
EP1419154B1 (en) * 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
EP1646635A1 (en) 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c
JP4227649B2 (ja) 2003-08-07 2009-02-18 ワイス Cci−779の位置選択的合成
EP1660081A1 (en) * 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
KR20070015544A (ko) * 2004-04-14 2007-02-05 와이어쓰 라파마이신 42-에스테르 유도체의 위치특이성 합성

Also Published As

Publication number Publication date
IL184560A0 (en) 2007-10-31
EP1856130A1 (en) 2007-11-21
RU2007129264A (ru) 2009-03-20
KR20070107030A (ko) 2007-11-06
AU2006213061A1 (en) 2006-08-17
GT200600044A (es) 2006-11-09
BRPI0607932A2 (pt) 2016-11-08
ZA200706628B (en) 2010-01-27
CA2595766A1 (en) 2006-08-17
CN101115759A (zh) 2008-01-30
TW200638932A (en) 2006-11-16
WO2006086172A1 (en) 2006-08-17
JP2008530090A (ja) 2008-08-07
MX2007009590A (es) 2007-09-12
PE20060996A1 (es) 2006-11-13
US20060178392A1 (en) 2006-08-10
US7442707B2 (en) 2008-10-28
NO20073725L (no) 2007-09-05
CR9257A (es) 2007-11-23

Similar Documents

Publication Publication Date Title
PE20060649A1 (es) Forma polimorfa ii de rapamicina y proceso de preparacion
CL2008002794A1 (es) Compuestos derivados de dihidropirimidina-2,4-(1h,3h)-diona; formas cristalinas, compuestos intermediarios; procedimiento de preparación de los compuestos intermediarios, composición farmacéutica; y su uso util para tratar hepatitis c en un mamífero.
AR045559A1 (es) Rapamicina amorfa 42- ester con 3- hidroxi-(hidroximetil)-2 acido metilpropionico y sus composiciones farmaceuticas
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
UY28695A1 (es) Derivados de difenilazetidona
ECSP077212A (es) Derivativas de pirimidina fusionado y compuestos del mismo como moduladores de receptores cxcr3, útil en prevención y tratamiento de trastornos y enfermedades inmuno-reguladores y inflamatorios
AR078674A1 (es) Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas
WO2012066502A1 (en) Processes for preparation of everolimus and intermediates thereof
PE20081465A1 (es) Procesos para la sintesis de isomeros individuales de cci-779 monopeg
UY29516A1 (es) Derivados de purina
UY32077A (es) Inhibidores de quinasa tipo polo
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
RU2007144531A (ru) Новые кристаллические формы тиотропийбромида
PY2238669A (es) Nueva piridina sustituida
PY2238680A (es) Nueva piridina sustituida
Ojika et al. Aplyronines D–H from the sea hare Aplysia kurodai: isolation, structures, and cytotoxicity
ECSP077306A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorios
CN108530474B (zh) 一类吡咯腙肼双氟硼荧光染料及其制备方法
AR040233A1 (es) Polimorfos inhibidores de xantina fosfodiesterasa v
Merkushev et al. A simple synthesis of benzofurans by acid-catalyzed domino reaction of salicyl alcohols with N-tosylfurfurylamine
WO2013124748A4 (en) Novel polymorphs of azilsartan medoxomil potassium
PY2265946A (es) Nueva (3-quinolil)-quinazolina
PY2265941A (es) Nueva (3-piridil)-quinazolina
Shibinskaya et al. Synthesis and biological activity of 7H-benzo [4, 5] indolo [2, 3-b]-quinoxaline derivatives

Legal Events

Date Code Title Description
FB Suspension of granting procedure